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Abstract 
Question: Does Nitisinone prevent the clinical progression of the Alkaptonuria?  
Findings: In this observational study on 39 patients, 2mg of daily nitisinone inhibited ochronosis and 
significantly slowed the progression of AKU over a three-year period. 
Meaning: Nitisinone is a beneficial therapy in Alkaptonuria  
Background: Nitisinone decreases homogentisic acid (HGA), but has not been shown to modify 
progression of Alkaptonuria (AKU).  
Methods: Thirty-nine AKU patients attended the National AKU Centre (NAC) in Liverpool for 
assessments and treatment. Nitisinone was commenced at V1 or baseline. Thirty nine, 34 and 22 AKU 
patients completed 1, 2 and 3 years of monitoring respectively (V2, V3 and V4) in the VAR group. 
Seventeen patients also attended a pre-baseline visit (V0) in the VAR group. Within the 39 patients, a 
subgroup of the same ten patients attended V0, V1, V2, V3 and V4 visits constituting the SAME Group.  
Severity of AKU was assessed by calculation of the AKU Severity Score Index (AKUSSI) allowing 
comparison between the pre-nitisinone and the nitisinone treatment phases.  
Results: The ALL (sum of clinical, joint and spine AKUSSI features) AKUSSI rate of change of 
scores/patient/month, in the SAME group, was significantly lower at two (0.32±0.19) and three 
(0.15±0.13) years post-nitisinone when compared to pre-nitisinone (0.65±0.15) (p<0.01 for both 
comparisons). Similarly, the ALL AKUSSI rate of change of scores/patient/month, in the VAR group, 
was significantly lower at one (0.16±0.08) and three (0.19±0.06) years post-nitisinone when compared 
to pre-nitisinone (0.59±0.13) (p<0.01 for both comparisons). Combined ear and ocular ochronosis rate 
of change of scores/patient/month was significantly lower at one, two and three year’s post-nitisinone in 
both VAR and SAME groups compared with pre-nitisinone (p<0.05). 
Conclusion: This is the first indication that a 2mg dose of nitisinone slows down the clinical 
progression of AKU. Combined ocular and ear ochronosis progression was arrested by nitisinone.  
Introduction 
Alkaptonuria (AKU) is a rare genetic deficiency of homogentisate dioxygenase (HGD), characterised by 
high circulating homogentisic acid (HGA), some of which is deposited in connective tissue as a 
pigmented polymer, during a process termed ochronosis [1,2]. The effects of ochronosis include 
premature arthritis, lithiasis, cardiac valve disease, fractures, muscle and tendon ruptures and osteopenia 
[3,4]. 
Current therapy is only palliative [5]. A potential agent called nitisinone has been shown to decrease 
circulating HGA [6,7,8] and to inhibit ochronosis in AKU mice [9,10]. Nitisinone which inhibits p-
hydroxyphenylpyruvate dioxygenase, the enzyme leading to formation of HGA, has been used for more 
than twenty years in the treatment of type-1 hereditary tyrosinaemia (HT-1) [11,12]. The dose of 
nitisinone that decreases HGA by greater than 95% is 2 mg daily, based on the experience of using 
nitisinone in the National Institute of Health, USA [6,7,8], and the SONIA-1 clinical study [13], and 
approximately ten to fifty times lower than the doses used in HT-1. NHS England has approved the use 
of off-label nitisinone 2 mg daily for the management of AKU in the National Alkaptonuria Centre 
(NAC) Liverpool, UK [14]. 
A previous study employing 2 mg dose of nitisinone, failed to demonstrate a benefit on a single non-
metabolic outcome, hip rotation [8]. The NAC is collecting data from a large number of assessments to 
calculate the severity of AKU using a validated semi-quantitative composite score termed AKUSSI 
(alkaptonuria severity scoring index) [15,16], which increases the likelihood of detecting an effect of 
nitisinone. 
Subjects and Methods 
The NAC was established in the Royal Liverpool University Hospital and funded by the Highly 
Specialised Services, NHS England, in April 2012. The lead author’s institutional audit committee 
approved the analysis of the NAC data (Audit no. ACO3836). 
Thirty-nine AKU patients attended the National AKU Centre (NAC) in Liverpool (Figure 1). Varying 
numbers attended yearly visits in this VAR group (or VAR; variable number of patients at each visit). 
Nitisinone 2mg was commenced at baseline (V1). Systematic assessments were carried out at all visits. 
Thirty-nine, 34 and 22 AKU patients completed 1, 2 and 3 years of monitoring respectively (V2, V3 and 
V4) after starting nitisinone. Seventeen patients (7 female and 10 male) also attended a pre-baseline visit 
(V0) in the VAR group; the duration between the V0 and V1 was 32.2 (±2.3) months. V1 (n = 39; mean 
age 47.3 (±2.3) years; 15 females; 24 male), V2 (n = 39; mean age 48.3 (±2.3) years; 15 females; 24 
male), V3 (n = 34; mean age 48.7 (±2.6) years; 14 females; 20 male), and V4 (n = 22; mean age 47.3 
(±3.4) years; 9 females; 13 male) visits in the VAR group had a full data set in which the AKUSSI was 
calculated.   
Within the 39 patients, a subgroup of the same ten patients attended V0, V1, V2, V3 and V4 visits 
constituting the SAME Group; the duration between V0 and the V1 was 36.7±2.2 months. Attendance 
thereafter in the NAC was once a year.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Plan of the National Alkaptonuria Service: *The VAR group V0 visit consisted of the 10 patients 
from the SAME group plus seven additional patients who attended the NAC twice without receiving 
nitisinone. The SAME refers to ten patients attending the research study between 2008 and 2011. The V1, 
V2, V3 and V4 refer to yearly visits to the NAC. The NIT 1, NIT 2 and NIT 3 refer to change scores per 
patient per year after one, two and three years of nitisinone therapy. The numbers of patients in each group, 
their mean age and years of follow-up are also shown in the figure. 
 
Change in scores between V0 and V1, V1 and V2, V1 and V3, and V1 and V4 represent follow-up 
without nitisinone, as well as one, two and three years of nitisinone therapy, termed PRENIT, NIT 1, 
NIT 2, and NIT 3 respectively. 
  n = 10                                                                              n = 10                  n = 10                  n = 10               n = 10 
V4  V3  V2   V1   
Difference in V1-V0 
(PRENIT) 
  
Difference in V2-V1 
(NIT 1) 
V0  
V0  
SAME GROUP 
VAR GROUP 
Difference in V3-V1 
(NIT 2) 
Difference in V4-V1 
(NIT 3) 
V4  V3  V2   V1   
PRE-NITISINONE  POST-NITISINONE 
Mean age 47.7±4.4 years  
                   n = 17                                                                                n = 39               n = 39                 n = 34                 n = 22 
Mean age 47.8±3.1 years                                                                47.3±2.3          48.3±2.3            48.7±2.6            47.3±3.4 
Assessments used in AKUSSI and assigned scores [13,14] (Table 1): Assessments and investigations 
detailed in Table 1 were carried out at V0, V1, V2, V3 and V4. The AKUSSI was developed during a 
study of AKU (UK Research Ethics Committee Number 07/Q1002/111) [15,16]. Ear and eye 
ochronosis, calculi (renal, prostate), osteopenia, fracture, ruptures (tendon/ligament/muscle), aortic 
valve disease, hearing impairment collectively constitute the CLIN category. Pain and scintigraphy 
scores in 14 joint areas, arthroscopy and joint replacements, comprise the JOINT category. Pain and 
scintigraphy scores in 6 areas including the spine, pubis and ribs comprise the SPINE category. The sum 
of CLIN, JOINT and SPINE scores constitute the ALL category. There is no upper maximal score as 
some features such as fractures are not finite. The original AKUSSI was modified by having improved 
scoring of eye ochronosis (superficial conjunctival and deep scleral), each episode of renal stone, aortic 
valves disease (mild, moderate and severe stenosis as well as sclerosis), a T-score equal to or less than -
1.1 for osteopenia, score for kyphosis given if Cobb angle was greater than 30º, and score for scoliosis 
given if Cobb angle was greater than 10º; in addition, some features such as heart failure, Parkinson’s 
disease, atrial fibrillation, other cardiac arrhythmias, strokes, skin pigment, teeth pigment, middle ear 
pigment, laryngeal pigment, and salivary stone, were excluded to improve consistency.  
 
 
 
FEATURE TEST FEATURE TEST 
Eye ochronosis: 
Right eye nasal* PHOTO Left eye nasal* PHOTO 
Right eye temporal* PHOTO Left eye temporal* PHOTO 
Ear ochronosis: 
Right ear** PHOTO Left ear** PHOTO 
Prostate stones (4 per episode) 
US/ 
HISTORY 
Kidney stones (4 per episode) US/ HISTORY 
Osteopenia (4) CT-BMD Hearing impairment (4) HISTORY 
Aortic sclerosis (6), Aortic stenosis (mild, moderate, severe) (8, 10, 12) ECHO 
Fracture (8 per fracture) HISTORY Muscle rupture (8 per rupture) HISTORY 
Ligament rupture ( 8 per rupture) HISTORY Tendon rupture (8 per rupture) HISTORY 
CLINICAL AKUSSI  
JOINT PAIN score (1 for each large joint area; 14 large joint areas) HISTORY 
Scintigraphic scan joint score (2 for each large joint; 14 large joint areas) 18F-PETCT 
Number of arthroscopies (2 each) HISTORY 
Number of joint replacements (4 each) HISTORY 
JOINT AKUSSI  
SPINAL PAIN score (2 each for cervical, thoracic, lumbar, sacroiliac) HISTORY 
Scintigraphic scan spine score (6 areas; 4 points for each area; pubic symphysis, costochondral, 
lumbar, thoracic, cervical, sacroiliac) 
18F-PETCT 
Kyphosis (4) X-RAY 
Scoliosis (4) X-RAY 
SPINE AKUSSI  
ALL AKUSSI (CLINICAL+JOINT+SPINE)  
Table 1. AKUSSI scoring in the NAC. The various clinical features were scored in the manner indicated 
in the table. The assessments included subjective pain scoring, photographs, history, ultrasound 
abdomen, echocardiogram, dual energy x-ray absorptiometry, x-ray spine and 18FPETCT scan. *Eye 
pigmentation: 1, 2 and 3 points for slight, moderate and marked conjunctival pigmentation and 4, 6 and 
8 points for scleral pigmentation; **Ear pigmentation: 2 and 4 points for slight and marked 
pigmentation. 
 
Off-label nitisinone usage: Nitisinone was commenced on day 3 of V1. Fasting serum and 24-hr urine 
samples were collected on days 2 and 4 and patients discharged on nitisinone 2 mg alternate days. 
Fasting serum and 24-hr urine were collected at month 3 post-nitisinone before patients started 
nitisinone 2 mg daily and at month 6 post-nitisinone. Fasting serum and 24-hr urine were thereafter 
collected at V2, V3, and V4. Supportive therapies such as analgesia (including neuromuscular blocks) 
and lifestyle advice were also provided in the NAC. Therefore, AKUSSI scores for JOINT, SPINE and 
ALL were also calculated without the pain scores (JOINTNP: NP meaning no pain scores, SPINENP 
and ALLNP) to determine if these treatments affected the results. Physiotherapy reinforced appropriate 
exercises to support optimal function. Dietetic management ensuring optimal protein intake was 
employed to minimise tyrosinaemia post-nitisinone. 
Chemical analysis: Only samples from 2012 onwards were available for assay. HGA was measured on 
acidified 24-hr urine (u-HGA24) and acidified serum (s-HGA) samples from each visit as previously 
described by tandem mass spectrometry [17,18]. 
Statistical analysis:  
Multiple visit data were subjected to repeated measures of variance ANOVA, and unpaired data by 
ANOVA with post hoc correction for multiple comparison as appropriate (Tukey Kramer).  
Results 
All patients had increased urine HGA confirming the diagnosis of AKU at V1. u-HGA24 concentrations 
decreased by 80.2 to 93.9% at all follow-up visits compared to V1 for the SAME and the VAR groups 
(p<0.01) (Figure S1). Similarly, s-HGA decreased by 80.2-89.3% at follow-up visits as compared to V1 
respectively in both the SAME and VAR groups (p<0.01; Figure S2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. s-HGA concentrations in SAME and VAR groups, Pre- and Post-Nitisinone. Scores are 
shown as box plots with and interquartile range. The level of significance of results is shown as 
*p<0.001. 
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Figure S2. u-HGA24 concentrations in SAME and VAR groups, Pre- and Post-Nitisinone. Scores are 
shown as boxplots with interquartile range. The level of significance of results is shown as *p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. s-TYR concentrations in SAME and VAR groups, Pre- and Post-Nitisinone. Scores are shown 
as boxplots with interquartile range. The level of significance of results is shown as *p<0.001. 
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Table S1. Numbers of events in Clinical AKUSSI category without pigment change in the SAME and 
VAR groups. Please note varying event numbers in varying numbers of patients in the VAR group. 
 
SAME Group (Table 2): At baseline the following numbers of events (in brackets) were observed in 
the SAME group: prostate stone (1), renal stones (2), osteopenia (10), fractures (9), tendon rupture (0), 
muscle rupture (3), ligament rupture (5), aortic sclerosis (5), aortic stenosis (3), hearing loss (4) and joint 
replacements (12) (Table S1). There was a significant increase in JOINT, JOINT WITHOUT PAIN, 
SPINE, ALL and ALL WITHOUT PAIN categories between V0 and V1 (Table 2). The CLIN and 
  SAME GROUP 
  
VAR GROUP 
  V0 
(n = 10) 
V1 
(n = 10) 
V2 
(n = 10) 
V3 
(n = 10) 
V4 
(n = 10) 
V0 
(n = 17) 
V1 
(n = 39) 
V2 
(n = 39) 
V3 
(n = 34) 
V4 
(n = 22) 
Prostate Stone 1 1 1 1 1 5 13 13 11 5 
Renal stone 2 2 2 2 2 6 6 6 7 6 
Osteopenia 7 10 10 10 9 11 27 27 27 14 
Fracture 7 9 10 11 14 9 21 24 23 21 
Tendon 
rupture 
0 0 0 0 0 1 5 7 6 0 
Muscle 
rupture 
3 3 3 3 3 5 5 7 8 5 
Ligament 
rupture 
4 5 5 5 5 6 8 8 8 6 
Aortic 
sclerosis 
3 5 4 4 4 6 14 12 10 8 
Mild Aortic 
Stenosis 
1 2 3 2 2 2 3 5 6 3 
Moderate 
Aortic Stenosis 
0 0 0 0 1 1 1 0 0 1 
Severe Aortic 
Stenosis 
0 1 1 1 1 0 2 2 1 1 
Hearing 
impairment 
3 4 4 5 5 4 11 11 12 10 
Arthroplasty 6 12 15 17 17 12 36 39 43 33 
SPINE WITHOUT PAIN showed a similar trend in the V0 and V1 comparisons. None of the other 
comparisons was significant. 
 
SAME PATIENT NUMBER GROUP (SAME) (n = 10) [Mean(SEM)] 
Categories V1 V0 V2 V3 V4 
CLIN 40.3 (7.7) 31.6 (6.3) 40.2 (8.3) 40.4 (8.7) 42.7 (10.7) 
JOINT 25.9 (3.4) 19.1 (3.0)* 28.5 (2.8) 28.1 (2.7) 27.5 (3.5) 
JOINT WITHOUT PAIN 20.0 (2.5) 14.0 (2.2)* 22.6 (2.5) 22.8 (2.6) 22.2 (2.9) 
SPINE 26.0 (2.8) 19.2 (2.9)* 27.2 (3.2) 28.2 (3.3) 27.4 (3.3) 
SPINE WITHOUT PAIN 20.8 (2.1) 16.0 (2.6) 22.0 (2.5) 22.4 (2.4) 22.0 (2.7) 
ALL 92.2 (12.6) 69.8 (11.0)** 95.9 (12.8) 96.7 (13.3) 97.6 (15.8) 
ALL WITHOUT PAIN 82.1 (11.0) 61.5 (10.1)** 84.8 (11.5) 85.6 (12.2) 86.9 (14.7) 
VARIABLE PATIENT NUMBER GROUP (VAR) [Mean(SEM)] (mean and SEM for any V category are different in each column) 
Categories V1 vs V0 (n=17) V1 vs V2 (n=39) V1 vs V3 (n=34) V1 vs V4 (n=22) 
CLIN 39.7(5.9) vs 32.5 (5.3) 29.5 (3.3) vs 29.6 (3.5) 29.9 (3.5) vs 31.2 (3.8) 28.9 (4.5) vs 31.1 (5.5) 
JOINT 26.8(3.2) vs 20.6 (3.1) 22.0 (1.9) vs 22.6 (1.9) 21.4 (2.1) vs 25.1 (1.9) 22.5 (2.9) vs 24.3 (3.2) 
JOINT WITHOUT PAIN 20.8(2.7) vs 16.0 (2.6) 16.5 (1.4) vs 17.3 (1.5) 16.5 (1.6) vs 19.8 (1.5) 17.4 (2.2) vs 19.2 (2.6) 
SPINE 26.0(2.5) vs 20.2 (2.7) 24.6 (1.8) vs 24.7 (1.9) 24.4 (2.0) vs 26.2 (2.1) 22.9 (2.7) vs 24.5 (3.0) 
SPINE WITHOUT PAIN 20.5(1.9) vs 16.7 (2.2) 20.1 (1.4) vs 20.4 (1.5) 20.0 (1.6) vs 21.3 (1.7) 18.7 (2.2) vs 19.8 (2.4) 
ALL 92.5(10.3)vs73.5(9.8)* 76.1 (6.0) vs 77.0 (6.1) 75.6 (6.5) vs 82.5 (6.6) 74.3 (8.9) vs 79.9 (10.1) 
ALL WITHOUT PAIN 80.2 (9.0) vs 64.5 (8.7) 66.0 (5.2)vs 67.3 (5.5) 66.4 (5.7)vs 72.3 (5.9) 65.0 (7.7) vs 70.1 (9.1) 
Table 2. SAME and VAR groups showing the scores [mean (SEM)] for the various components of the 
AKUSSI (all comparisons against V1, repeated measures ANOVA; n=10; Tukey Kramer multiple 
comparison), *p<0.05; ** p<0.01; *** p<0.001, **** p<0.0001. Mean and SEM for any VAR category 
are different in each column. 
 
SAME Group score change over time (Table 3, Figure 2a): The score change per patient per month 
showed lower values for NIT-1, NIT-2 and NIT-3 compared against PRE-NIT in CLIN, ALL and ALL 
WITHOUT PAIN categories. These comparisons showed a similar lower trend from PRE-NIT to NIT-3 
for all other categories. Change in combined ear and eye pigment scores was lower during nitisinone 
usage (Figure 3). 
Table 3. SAME and VAR groups showing the change scores per patient per month (mean±SEM) for the 
various components of the AKUSSI (repeated measures ANOVA; n=10; Tukey Kramer multiple 
comparison), *p<0.05; ** p<0.01; *** p<0.001.  
  
SAME PATIENT NUMBER GROUP (SAME) (n = 10) 
Categories PRENIT vs NIT  1 PRENIT vs NIT  2 PRENIT vs NIT  3 
CLIN 
0.249 (0.08) vs  0.002 
(0.08)*** 
0.249 (0.08)vs 0.004 (0.06)*** 0.249 (0.08) vs 0.067 (0.1)** 
JOINT 0.206 (0.08) vs 0.192 (0.12) 0.206(0.08) vs 0.088 (0.05) 0.206 (0.08) vs 0.041 (0.03) 
JOINT WITHOUT PAIN 0.180 (0.07) vs 0.208 (0.09) 0.180 (0.07) vs 0.115 (0.06) 0.180 (0.07) vs 0.06 (0.03) 
SPINE 0.192 (0.06) vs 0.104 (0.17) 0.192 (0.06) vs 0.09 (0.08) 0.192 (0.06) vs 0.039 (0.05) 
SPINE WITHOUT PAIN 0.134 (0.04) vs 0.100 (0.15) 0.134 (0.04) vs 0.067 (0.07) 0.134 (0.04) vs 0.033 (0.05) 
ALL 0.647 (0.14) vs 0.294 (0.17)* 0.647 (0.14) vs 0.184 (0.10)** 0.647(0.14) vs 0.146 (0.13)** 
ALL WITHOUT PAIN 0.561 (0.11) vs 0.306 (0.15) * 0.561 (0.11) vs 0.186 (0.11)** 0.561(0.11) vs 0.159(0.14)*** 
VARIABLE PATIENT NUMBER GROUP (VAR) 
Categories 
PRENIT vs NIT  1 
n=17 vs 39 
PRENIT vs NIT  2 
n=17 vs 34 
PRENIT vs NIT  3 
n=17 vs 22 
CLIN 0.221 (0.06)vs 0.016 (0.05) 0.221 (0.06) vs 0.053 (0.04) 0.221 (0.06) vs 0.061 (0.05) 
JOINT 0.188 (0.06) vs 0.045 (0.06) 00.188 (0.06) vs 0.156 (0.04) 0.188 (0.06) vs 0.051 (0.03) 
JOINT WITHOUT PAIN 0.159 (0.05) vs 0.066 (0.04) 0.159 (0.05) vs 0.135 (0.03) 0.159 (0.05) vs 0.053 (0.03) 
SPINE 0.183 (0.05) vs 0.013 (0.06) 0.183 (0.05) vs 0.078 (0.03) 0.183 (0.05) vs 0.043 (0.03) 
SPINE WITHOUT PAIN 0.273 (0.06) vs 0.026 (0.04) 0.273 (0.06) vs 0.054 (0.03) 0.273 (0.06) vs 0.031 (0.03) 
ALL 0.591 (0.13) vs 0.074 (0.1)** 0.591 (0.13) vs 0.287 (0.06) 0.591 (0.13) vs 0.154 (0.07)* 
ALL WITHOUT PAIN 0.485 (0.11) vs 0.108 (0.08)* 0.485 (0.11) vs 0.243 (0.06) 0.485 (0.11) vs 0.141 (0.08) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. (A) Components of AKUSSI Change Scores per patient per month in SAME group (n=10). 
Scores are shown as boxplots with interquartile range. The levels of significance of results are shown as 
*p<0.05; **p<0.01; ***p<0.001. (B). Components of AKUSSI Change Scores in VAR group (n variable). 
Scores are shown as boxplots with interquartile range. The levels of significance of results are shown as 
*p<0.05; **p<0.01. The score change tends to be slower following nitisinone usage both in the SAME 
and the VAR groups across CLIN, JOINT, SPINE and ALL categories. 
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 VAR Group: At baseline the following numbers of events (in brackets) were observed in the VAR 
group: prostate stone (13), renal stones (6), osteopenia (27), fractures (21), tendon rupture (5), muscle 
rupture (5), ligament rupture (8), aortic sclerosis (14), aortic stenosis (6), hearing loss (11) and joint 
replacements (36) (Table S1). There was a significant increase (Table 2) in ALL category between V0 
and V1, although a similar pattern was observed for other categories between V0 and V1. There was no 
evidence of differences for other comparisons including V2, V3 and V4. 
VAR Group score change over time (Table 3; Figure 2b): The score change per patient per month 
showed lower values with NIT-1, NIT-2 and NIT-3 compared against PRE-NIT in almost all categories. 
Comparisons were significantly different (Table 3) between NIT-1 and PRE-NIT for ALL and ALL 
WITHOUT PAIN categories; similarly, significant differences were observed between NIT-3 against 
PRE-NIT for the ALL category. Change in combined ear and eye pigment scores was lower during 
nitisinone usage (Figure 3). 
  
  
 
 
 
 
 
 
 
Figure 3. Change in combined eye and ear ochronosis scores per patient per month in SAME and VAR 
groups in the PRENIT, NIT 1, NIT 2 and NIT 3 categories. Significant decrease in rate of change seen 
following years of nitisinone usage (* p<0.05, **p<0.01, ***p<0.001). 
 
Overall, the major finding is one of consistent change in CLIN, JOINT, JOINT NP, SPINE, SPINENP, 
ALL and ALLNP in the same direction indicating slower progression post-nitisinone in SAME and 
VAR groups. Changes in SAME and VAR groups (Table S1) have been described in detail. Despite 
high prevalence of disease features, due to numbers of patients not being large and due to the 
unpredictability of events, the incidence of new events such as fractures, ruptures, renal stones and joint 
replacements are low. The mean age of the groups was around 48 years in all categories and comparable 
in both the SAME and VAR groups.  
Discussion 
It is well established that nitisinone is effective in reducing circulating HGA in humans [6,8,13], and 
preventing ochronosis in AKU mice [9,10], but there is no data to date demonstrating a decrease in 
ochronosis or a reduction in the rate of disease progression in AKU patients. A previous nitisinone 
interventional clinical study of AKU patients was inconclusive for the primary outcome, namely range 
of motion of the hip joint, despite clear metabolic efficacy of nitisinone 2 mg decreasing daily urine 
HGA excretion by more than 95% [8].  
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 Introne et al [8] compared the lateral rotation of the hip between the nitisinone treated group and the 
untreated group to conclude on clinical efficacy of nitisinone in AKU. Due to the ultra-rare nature of 
AKU, a disease with a frequency of 1 in 250,000 to 1 in 1,000,000, it would be difficult to have a 
sufficiently large number of patients to demonstrate a difference in a single end point such as lateral 
rotation of the hip [19]. Instead, analysis of the data carried out and presented in this manuscript from 
the NAC aimed to look at a composite end point.  
The present data analysis is an audit of a service using nitisinone off-label. Our patient groups are highly 
comparable in terms of numbers of individuals and duration of nitisinone therapy to the NIH nitisinone 
intervention study, where 20 patients received nitisinone for three years and 20 did not [8]. Nitisinone is 
used in the NAC at the same dose as in the NIH nitisinone interventional study. By calculating the 
difference in scores between V0 and V1 (PRENIT), it was possible to carry out the assessment of 
disease progression in both SAME and VAR groups over 3 years without treatment with nitisinone, 
which is similar to the no-treatment group in the NIH study. 
Nitisinone decreased urine HGA by greater than 80% in both the SAME and the VAR groups (Fig S2). 
This was only slightly less than in the nitisinone intervention study [8], and is reasonable considering 
that the present data analysis is from a service evaluation rather than a research study. The magnitude of 
reduction in HGA needed for optimal benefit, thus the dose of nitisinone needed to make a clinical 
difference, is not currently known. 
In the PRENIT score change analysis, the major finding is the consistent increase in the AKUSSI 
between the V0 to V1 comparisons across all categories. This suggests progression of AKU in patients 
who are nitisinone-naive. It is noteworthy that none of the other AKUSSI categories showed a 
significant difference at any follow-up visits once patients started treatment with nitisinone, both in the 
SAME and the VAR groups. This suggests that nitisinone 2 mg daily is having a similar effect in 
slowing the progression of AKU both in the SAME and the VAR groups. This is further supported by 
the finding of a significant and progressively slower rate of AKUSSI score change per patient per month 
while on treatment with nitisinone, with the longer the duration of nitisinone usage showing greater 
decrease in rate of change per patient per month, both in the SAME and the VAR groups (Figure 2a, b). 
The change in combined ear and eye ochronosis scores were lower post-nitisinone both in the SAME 
and the VAR groups (Figure 3). This demonstrates, for the first time in humans, that the process of 
ochronosis is retarded by nitisinone, as it has been shown to do in AKU mice [9,10]. 
The differences in ALL AKUSSI scores between the V0 and V1 in both the SAME (p<0.01) and the 
VAR (p<0.05) groups were significant. To translate these changes in terms of clinical significance, the 
total score change between the V0 and V1 score in the SAME and VAR groups, were respectively 224 
and 278.8, hypothetically equivalent to 56 (5.6 per patient) and 69.7 (4.1 per patient) joint replacements 
[or 18.7 (1.87 per patient) and 23.2 (1.36 per patient) severe cases of aortic stenosis or other disease 
feature equivalents] without nitisinone treatment. Following 3 years of treatment with nitisinone the 
total score change between the V0 and V1 in the SAME and VAR groups were respectively 54 and 
123.2, hypothetically equivalent to 13.5 (1.35 per patient) and 30.8 (1.81 per patient) joint replacements 
[or 4.5 (0.45 per patient) and 10.3 (0.61 per patient) cases of severe aortic stenosis or other disease 
feature equivalents] respectively. To capture the number of joint replacements in the range of 56 and 
69.7, would require an enormous number of AKU patients, not feasible in an ultra-rare disease. 
However, a significant change in the composite AKUSSI score, which reflects pathology based on a 
common mechanism namely HGA-related ochronosis, allows for a better assessment of efficacy of 
treatments such as nitisinone. 
In the SAME group, the events leading to the CLIN score changes between V0 and V1 is shown 
(numbers of each event in bracket) (Table S1). The change in CLIN features at each visit in the SAME 
and VAR groups are also shown. These highlight the high prevalence of features in a slowly progressive 
condition, where the relatively lower incidence of these features, highlight the difficulty of using a 
single feature to determine outcomes, and thus supporting the use of a composite score approach to 
evaluate efficacy of therapy. 
HGA by itself causes features of AKU such as lithiasis. Nitisinone by decreasing HGA should prevent 
HGA stone formation. In addition, nitisinone should decrease the formation of ochronotic pigment by 
decreasing HGA and thereby decrease morbidity. The data from the SAME and VAR groups, showing 
that the eye and ear pigment changes were stabilised, strongly suggest this is the case. 
The AKUSSI is a semi-quantitative tool based on categorical and partially continuous scoring of key 
features of AKU. The AKUSSI employed in the data analysis presented in this manuscript has been 
adapted from the one previously published [15,16], by removal of less specific disease features such as 
congestive heart failure, Parkinson’s disease, strokes and electrocardiographic abnormalities. The ocular 
ochronosis assessment has been improved. Most of the scores in the AKUSSI were objective based on 
investigations, although there were a few subjective features such as joint pains.  
As these data were obtained as part of service delivery assessment, there are inevitable limitations. All 
patients were eligible to receive nitisinone and therefore there was no randomization of treatment 
intervention. However, a group of patients were followed up for a near-equal duration prior to and 
following nitisinone treatment, minimising bias. The NAC patients also received individually tailored 
treatments such as dietary advice, physiotherapy, analgesia and possibly nerve blocks and there is a 
theoretical but unlikely possibility that these additional treatments could have led to the improvements 
observed. This is why JOINT, SPINE and ALL AKUSSI were also calculated without pain scores as in 
JOINT NP, SPINE NP and ALL NP AKUSSI scores (Table 2 and 3). It is noteworthy that despite 
removal of pain scores the statistical significance of results remained relatively unaffected. It is also 
unlikely that any interventions for pain relief carried out in the NAC visit lasted a full year in this annual 
service visit model. It should be noted that relieving pain might also have adversely affected outcomes, 
as pain is an important defence against unnecessary usage of a damaged tissue, allowing the affected 
tissue to rest, heal and repair itself. The ochronotic tissue in AKU is brittle and breaks down easily [20] 
and any treatment that does not address the underlying pathophysiology is likely to be palliative at best 
and harmful at worst. All patients were also free to receive further treatments as needed locally after 
their NAC visit, both before and during nitisinone therapy. For all these reasons we believe that treating 
analgesia in the NAC was not a confounder in the analysis of results. 
In the NAC, lower protein diet was employed in managing tyrosinaemia after nitisinone therapy. 
However, there is little reliable literature attesting to efficacy of diet in modifying AKU especially in 
adults [8]. Physiotherapy like analgesia is palliative at best and should not modify ochronosis as there is 
no plausible mechanism to alter disease progression.  
There were no HGA measurements in urine or serum from the V0 visits as samples were not acid 
stabilised and stored. However, we do not believe that this is a serious failing as the literature on 
metabolic efficacy is overwhelmingly established and all patients had proven AKU.  
Despite these limitations, the data show that 2 mg of daily nitisinone decreases the clinical progression 
of AKU over the three-year period. We have been able to show for the first time that nitisinone not only 
decreases HGA in AKU, but also reduces the rate of progression of what is believed to be an irreversible 
disease [10]. We have also shown for the first time that nitisinone arrests ochronosis, the cause of tissue 
damage in AKU.  
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